All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china | |
Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng | |
2019 | |
卷号 | 70 |
会议录 | JOURNAL OF HEPATOLOGY |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 0168-8278 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3597033 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Wei, Lai,Xu, Xiaoyuan,Guan, Yujuan,et al. All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论